Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn:
“Congratulations to Van Morris and the study team on the JCO publication of NCI9673 Part B in metastatic anal squamous cell carcinoma.
This study shows what cooperative group science can achieve in rare cancers—even through COVID.
The limited added benefit of dual checkpoint blockade in refractory disease raises the possibility of immune escape and pushes us to rethink where immunotherapy may matter most. Trials like NCT03233711, testing adjuvant nivolumab after definitive chemoradiation, may help answer that.
Grateful to have contributed to this collaborative effort.”
Title: NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
Authors:
You can read the full article in JCO ASCO.
More posts about GI Cancers.